Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-Titer Anti-ZSCAN1 Antibodies in a Toddler Clinically Diagnosed with Apparent Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome.
Tocan V, Nakamura-Utsunomiya A, Sonoda Y, Matsuoka W, Mizuguchi S, Muto Y, Hijioka T, Nogami M, Sasaoka D, Nagamatsu F, Oba U, Kawakubo N, Hamada H, Mushimoto Y, Chong PF, Kaku N, Koga Y, Sakai Y, Oda Y, Tajiri T, Ohga S. Tocan V, et al. Among authors: hijioka t. Int J Mol Sci. 2024 Feb 29;25(5):2820. doi: 10.3390/ijms25052820. Int J Mol Sci. 2024. PMID: 38474067 Free PMC article.
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral.
Matsumae T, Kodama T, Tahata Y, Myojin Y, Doi A, Nishio A, Yamada R, Nozaki Y, Oshita M, Hiramatsu N, Morishita N, Ohkawa K, Hijioka T, Sakakibara M, Doi Y, Kakita N, Yakushijin T, Sakamori R, Hikita H, Tatsumi T, Takehara T. Matsumae T, et al. Among authors: hijioka t. Cancers (Basel). 2023 Jan 11;15(2):463. doi: 10.3390/cancers15020463. Cancers (Basel). 2023. PMID: 36672412 Free PMC article.
Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis.
Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Hagiwara H, Oshita M, Imai Y, Hiramatsu N, Mita E, Kaneko A, Miyazaki M, Ohkawa K, Hijioka T, Fukui H, Ito T, Yamamoto K, Doi Y, Yoshida Y, Yamada Y, Yakushijin T, Tatsumi T, Takehara T; Osaka Liver Forum. Tahata Y, et al. Among authors: hijioka t. Dig Dis Sci. 2023 May;68(5):2115-2122. doi: 10.1007/s10620-022-07629-y. Epub 2022 Dec 16. Dig Dis Sci. 2023. PMID: 36526814
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis.
Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Nozaki Y, Oshita M, Hiramatsu N, Miyazaki M, Mita E, Yamamoto K, Ohkawa K, Kaneko A, Ito T, Doi Y, Yakushijin T, Hijioka T, Fukui H, Imanaka K, Yoshida Y, Yamada Y, Tatsumi T, Takehara T. Tahata Y, et al. Among authors: hijioka t. Hepatol Res. 2022 Oct;52(10):824-832. doi: 10.1111/hepr.13806. Epub 2022 Jul 8. Hepatol Res. 2022. PMID: 35749289
Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination-authors' reply.
Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T. Myojin Y, et al. Among authors: hijioka t. Aliment Pharmacol Ther. 2022 Apr;55(8):1061-1062. doi: 10.1111/apt.16862. Aliment Pharmacol Ther. 2022. PMID: 35362133 No abstract available.
Letter: evaluation and proposed reclassification of HCC prediction model of Tahata et al. in chronic hepatitis C genotype 4 patient. Authors' reply.
Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Oshita M, Ohkawa K, Hijioka T, Fukui H, Ito T, Doi Y, Yamada Y, Yakushijin T, Yoshida Y, Tatsumi T, Takehara T; Osaka Liver Forum. Tahata Y, et al. Among authors: hijioka t. Aliment Pharmacol Ther. 2022 Jan;55(2):258-259. doi: 10.1111/apt.16721. Aliment Pharmacol Ther. 2022. PMID: 34970764 No abstract available.
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.
Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T. Myojin Y, et al. Among authors: hijioka t. Aliment Pharmacol Ther. 2022 Feb;55(4):422-433. doi: 10.1111/apt.16691. Epub 2021 Nov 23. Aliment Pharmacol Ther. 2022. PMID: 34812502 Clinical Trial.
Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals.
Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Oshita M, Ohkawa K, Hijioka T, Fukui H, Ito T, Doi Y, Yamada Y, Yakushijin T, Yoshida Y, Tatsumi T, Takehara T; Osaka Liver Forum. Tahata Y, et al. Among authors: hijioka t. Aliment Pharmacol Ther. 2021 Nov;54(10):1340-1349. doi: 10.1111/apt.16632. Epub 2021 Oct 7. Aliment Pharmacol Ther. 2021. PMID: 34618934
78 results